Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Acceleron Pharma (XLRN), DENTSPLY SIRONA Inc (XRAY) and Advaxis (ADXS).
Acceleron Pharma (XLRN)
In a report released today, Edward White from H.C. Wainwright maintained a Buy rating on Acceleron Pharma, with a price target of $66. The company’s shares closed yesterday at $46.26.
White noted:
“We are lowering our price target to $66, from $67, due to the company’s decision to discontinue the development of ACE-2494. ACE-2494 contributed less than $1 to our valuation but due to rounding, the impact to our price target was $1.”
According to TipRanks.com, White is a 5-star analyst with an average return of 14.9% and a 49.1% success rate. White covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals Inc, Spectrum Pharmaceuticals, and Aileron Therapeutics Inc.
Acceleron Pharma has an analyst consensus of Strong Buy, with a price target consensus of $73, which is a 57.8% upside from current levels. In a report released yesterday, Piper Jaffray also maintained a Buy rating on the stock with a $74 price target.
See today’s analyst top recommended stocks >>
DENTSPLY SIRONA Inc (XRAY)
In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Hold rating on DENTSPLY SIRONA Inc, with a price target of $49. The company’s shares closed yesterday at $50.26, close to its 52-week high of $51.13.
Selvaraju noted:
“Our price target is derived from a comparable universe-based approach, which utilizes a price-to-earnings (P/E) multiple calculated from a group of peer companies in the medical and dental equipment arenas.”
According to TipRanks.com, Selvaraju is a 3-star analyst with an average return of 1.5% and a 38.6% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Biospecifics Technologies Corp, EyePoint Pharmaceuticals Inc, and Bausch Health Companies Inc.
Currently, the analyst consensus on DENTSPLY SIRONA Inc is a Moderate Buy with an average price target of $51.60.
Advaxis (ADXS)
H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Hold rating on Advaxis today and set a price target of $4.30. The company’s shares closed yesterday at $4.06, close to its 52-week low of $2.72.
Ramakanth commented:
“We maintain our Neutral rating of ADXS and adjust our 12-month price target to $4.30 per share, compared to no target previously. We derive our price target based on the average of two valuation methods: (1) price-sales multiple (6x 2026 sales estimate at 20% discount); and (2) price-earnings multiple (19x 2026 earnings estimate at 20% discount). (1) clinical; (2) financial; (3) regulatory; (4) commercial; and (5) intellectual property. Advaxis, Inc.”
According to TipRanks.com, Ramakanth is ranked 0 out of 5 stars with an average return of -8.0% and a 32.5% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Diffusion Pharmaceuticals Inc, IntelGenx Technologies, and Gritstone Oncology Inc.
Currently, the analyst consensus on Advaxis is a Hold with an average price target of $6.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
